Drone Delivery Already Becoming A Pharmaceutical Reality

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...
- Advertisement -

The last couple of years have been stressful for any industry you talk about. That said, there is one sector which has proven to be starkly different, and that’s pharmaceuticals. The Indian spectrum in any industry sphere is worth a case study. There’s a fine scene of rapid techno-transformation and digitisation taking place, and then you have the hard-to-reach rural populace, which, leave alone the development, doesn’t even have access to primary or basic healthcare.

The idea of on-demand drone delivery is an innovation that not only is revolutionary but also paves the path for many young startups to build their technology lines that help it become more efficient, inexpensive, and valuable for all. When we say pharmaceuticals in particular, drone delivery is the latest trend picking up, but will it find that grip on the tarmac? That needs to be seen.

One such expert talking about drones and their technological superiority is TPC Packaging Australia’s Arnold George, who calls them exciting and a good technology to make use of and get into places. However, he counters his excitement with the fact that is drone technology in today’s India really required when every village is connected. The drones have a maximum capacity to travel around 150–200 kilometers, but whether there is enough air space available is what he points at. He calls it an issue, and a real one at that, when there are more drones in the air, with more accidents, all leading to more danger to human lives.

Add the environmental sustainability concerns to it, as they are made up of plastic and metal, and you will begin to think of EVs as being a better bet than drones in the years to come.

The Indian civil aviation ministry last year in July made updates to the drone rules when it comes to making corridors for them for cargo package deliveries. The announcement made by the ministry puts forth an increase in weight from 300 kg to 500 kg, which would cover taxis as well.

Director of Business Development at Softbox Systems, Pavan Kumar, says that if human perception and tangibility change in India, that’s when drones and robots will have to be brought in to work on their behalf. He believes that full-fledged drone delivery and the technology that supports it are ten years away, but not for immediate use.

Gurugram-based TechEagle, a startup drone company, recently collaborated with the Meghalaya government to carry out the country’s first e-VTOL drone delivery when it comes to lifesaving meds. The company also received approval from the south Indian state of Telangana in association with the World Economic Forum and NITI Ayog to deliver vaccines and medical supplies across the region.

Arnold George adds that, on a more futuristic note, the shelf life of a drone needs to be compared to that of an EV, thereby calculating the risk involved. Besides an apt implementation, he says, the thought of recycling the drone must be paid heed to. This year has already seen innumerable Omicron cases across India, which has further planted new challenges for the pharmaceutical industry to keep on time and consistent delivery of medicines and vaccines a top priority.

When we talk about delivery in any space, of any product, supply chain transparency and visibility have been significant drivers. The supply chain has undoubtedly seen unimaginable disruptions across the globe, and this element represents one of the major challenges that pharmaceuticals are facing today.

George adds that becoming a one-stop solution is all that one looks out to have. When it comes to the domestic point of sale, no one knows what temperature the medicine is being delivered at, and there isn’t any visibility in that regard. Education, as per him, is the most pivotal of all the other things that the domestic landscape must have.

Continuing with it, George maintains that in regions like Europe, Singapore, and the US, there is proper visibility maintained w.r.t product visibility, temperature, etc. till the time the drug reaches the drugstore. All that the buyers have to do is scan the QR code to get to know the temperature that is maintained post-manufacturing of the drug. This is the level of visibility that is witnessed across the developed nations, but for a country like India to get to that level, some kind of education will be required. In 2022, it is expected that Pharma Logistics will be home to many improvements and upgrades. As per Sanjay Sharma, Vice President of Coldman Logistics, imports and exports may play a significant role in the pharmaceutical logistics spectrum. India’s exports have increased by 18%, which will aid in the growth of air and sea trade. There is some traction seen in warehouses domestically as well. Sharma adds that there are many pharmaceutical companies evolving and focusing on upscaling their quality infrastructure and, at the same time, getting hold of quality assurance services. The infrastructure space, as of now, happens to be price-driven and also lacks the quality and upkeep standards that are required. Now is the time for the existing infrastructure to be shifted to modern warehouses that in turn offer efficient and safe handling, better flexibility, and proper optimisation of the vertical space.

Coldman has already started to see a demand when it comes to warehousing requirements and also the trend in micro delivery. This has prompted them to focus on the BTS project and customise it as per client and temperature requirements.

Pavan Kumar from Softbox Systems adds that the last two years have seen pharmaceutical logistics struggling, especially in the cold chain arena. Air freight rates have added some stress already, and if things come back to normal this year, one can surely be optimistic about air and sea freight logistic challenges getting resolved. Innovations, especially in the logistic sector, are what everyone wants to have and even strives for. Everybody in the supply chain, from manufacturers to producers, distributors, and forwarders, is looking to get on the same page and thereby work towards better supply chain management as well as smooth logistics.

Arnold George says that there are three segments where he thinks signs are positive. The growth of the warehousing sector in India, the growth of the logistic companies and the emphasis on controlling temperature. Reefer vehicles have already witnessed a 15% constant growth in India, which, according to him, is a positive side. Finally, the traditional use of packaging is what should be upgraded by education.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...

Danaher Prepares to Introduce Advanced AI-Powered Laboratory

In a significant step for pharmaceutical research, Danaher has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »